Navigation Links
Neurologix Reports Third Quarter 2010 Financial Results
Date:11/12/2010

when, or if, the Company will be able to successfully receive approval from the FDA on its Investigational New Drug Application to commence a Phase 1 clinical trial for the treatment of epilepsy.
  • There is no assurance as to when, or if, the Company will be able to successfully complete the required preclinical testing of its gene therapy for the treatment of depression or Huntington's disease to enable it to file an Investigational New Drug Application with the FDA for permission to begin a Phase 1 clinical trial or that, if filed, such permission will be granted.

  • Other factors and assumptions not identified above could also cause the actual results to differ materially from those set forth in the forward-looking statements. Additional information about factors that could cause results to differ materially from management's expectations is found in the section entitled "Risk Factors" in the Company's 2009 Annual Report on Form 10-K. Although the Company believes these assumptions are reasonable, no assurance can be given that they will prove correct. Accordingly, you should not rely upon forward-looking statements as a prediction of actual results. Further, the Company undertakes no obligation to update forward-looking statements after the date they are made or to conform the statements to actual results or changes in the Company's expectations.Contact:NeurologixMarc Panoff, 201-592-6451Chief Financial Officermarcpanoff@neurologix.net-- Financial tables to follow--NEUROLOGIX, INC.
    (A Development Stage Company)
    BALANCE SHEETS
    (Amounts in thousands, except share and per share amounts)September 30,
    2010December 31,
    2009(Unaudited)ASSETSCurrent assets:Cash and cash equivalents

    $3,004

    $9,637Prepaid expenses and other current assets

    158

    395Total current assets

    3,162

    10,032Equ
    '/>"/>

    SOURCE Neurologix, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. New Details Presented at the World Parkinson Congress on Neurologixs Successful Phase 2 Trial of Gene Therapy for Parkinsons Disease
    2. Research Published in Science Translational Medicine Underscores Value of Depression Gene Therapy License Held by Neurologix
    3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
    4. Spherix Reports Second Quarter Earnings
    5. Tapestry Reports Second Quarter 2007 Results
    6. Callisto Reports on Second-Quarter 2007 Milestones
    7. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
    8. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
    9. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
    10. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
    11. Biopure Reports on Meeting with the FDA
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/28/2015)... Denmark and ATLANTA , August ... the US Food and Drug Administration (FDA) cleared the MagVita ... in adult patients who have failed to receive satisfactory improvement ... a non-invasive technique for stimulating neural tissue in the part ... Disorder. The procedure has been proven safe and effective and ...
    (Date:8/28/2015)... y LONDRES, 28 de agosto de ... PHIA) anunció hoy su participación en el  Congreso ... sus soluciones cardiológicas más recientes y novedosas, entre ... que conectan a las personas y la tecnología ... ayudar a diagnosticar, guiar los tratamientos y permitir ...
    (Date:8/27/2015)... FRANKLIN, Mass. , Aug. 27, 2015 /PRNewswire/ ... in the KSSTA Knee Journal, compared the Arthrosurface ... "inlay" Arthroplasty design, versus an "onlay" design implant ... showed similar improvements in function and pain scores, ... showed progression of osteoarthritis (OA). However, 53% of ...
    Breaking Medicine Technology:Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 2Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 3Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 2Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 3Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 4Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 5Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 2Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 3
    ... Osteotech, Inc. (Nasdaq: OSTE ), a leader in ... announced it is highlighting three procedure-specific MagniFuse(TM) bone grafting products ... Society (NASS) 2009 Annual Meeting, taking place November 10th through ... been used in 40 spinal surgeries in the ...
    ... Inc. (Nasdaq: VVUS ) today announced that Timothy Morris, chief ... Lazard Capital Markets 6th Annual Healthcare Conference. , The VIVUS presentation ... on Wednesday, November 18, 2009 at 1:45 p.m. ET. A ... at http://ir.vivus.com . , About VIVUS ...
    Cached Medicine Technology:Osteotech Highlights Three Procedure-Specific MagniFuse(TM) Bone Grafting Products at the NASS 2009 Annual Meeting 2Osteotech Highlights Three Procedure-Specific MagniFuse(TM) Bone Grafting Products at the NASS 2009 Annual Meeting 3Osteotech Highlights Three Procedure-Specific MagniFuse(TM) Bone Grafting Products at the NASS 2009 Annual Meeting 4Osteotech Highlights Three Procedure-Specific MagniFuse(TM) Bone Grafting Products at the NASS 2009 Annual Meeting 5VIVUS to Present at Lazard Capital Markets Healthcare Conference 2
    (Date:8/31/2015)... , ... August 31, 2015 , ... ... introduces the Talent Management Division , a department devoted to helping organizations ... department. Talent management goes beyond selection, and The Brooks Group believes in offering ...
    (Date:8/31/2015)... ... 2015 , ... According to book reviewer Angie Santangeloon , Dr. ... Cancer is an excellent resource for everyone since one in three persons will ... in explaining what cancer is in a easy to understand medically accurate way. The ...
    (Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... ... excited to establish its first Digital Hub in North America, now open in ... selecting Florida,” stated Founder and CEO John Campbell. “Jacksonville’s lifestyle, waterways and beautiful ...
    (Date:8/31/2015)... CO (PRWEB) , ... August 31, 2015 , ... Adult ... potential Denver area dermatology patients of the treatments and services available to ... patients by utilizing an innovative and ‘responsive design’ that allows visitors to view the ...
    (Date:8/31/2015)... , ... August 31, 2015 , ... TheHardwareCity.com is pleased ... tools set . , These home repair tool sets are manufactured by Allied Tools. ... around the house. The tri-fold tool set allows yard and house work to be ...
    Breaking Medicine News(10 mins):Health News:The Brooks Group Introduces Talent Management Division 2Health News:The Brooks Group Introduces Talent Management Division 3Health News:New Book The Cancer Solution Is a Must Read for Everyone Affected by Cancer 2Health News:Global Digital Opens USA Digital Agency Hub 2Health News:Adult & Pediatric Dermatology Launches Responsive Design Website 2Health News:Adult & Pediatric Dermatology Launches Responsive Design Website 3Health News:TheHardwareCity.com Now Offering Allied 49032 25 Piece Tri-Fold Tool Set 2
    ... , NANJING, China, June 19 ... a leading manufacturer and supplier of branded generic and,innovative ... annual,report on Form 20-F for the year ended December ... 18, 2009. The annual report can be accessed on,the ...
    ... ... will be introducing ten (10) new products at the 26th Annual ASMBS scheduled for June ... ... introducing ten (10) new products at the 26th Annual ASMBS scheduled for June 21-26 in ...
    ... Georgia facility to offer new choice in cancer treatment with fully ... 18 Cancer Treatment Centers of America (CTCA) announced today that ... cancer treatment hospital that will serve patients in the Southeast and ... View the Multimedia News Release, go to: http://www.prnewswire.com/mnr/cancercenter/38837 ...
    ... traumatic brain injury (TBI) has reached critical levels in ... of Neurotrauma focuses on the intensive efforts to ... the cause and effects of explosive blast TBI. This ... peer-reviewed journal published by Mary Ann Liebert, Inc., is ...
    ... , Senator John D. Rockefeller IV and Senator Bob Corker ... YORK, June 18 The American Society of Interventional ... All Schedules Prescription Electronic Reporting (NASPER) Act has received ... Virginia and Senator Bob Corker of Tennessee. , ...
    ... (Nasdaq: MEDQ ) has announced it has added ... Chief Information Officer. , , "As CIO, ... and development resources are aligned with its strategic and operational ... for profitable revenue and market share growth," says Peter Masanotti, ...
    Cached Medicine News:Health News:Bariatric Advantage to Introduce Ten (10) New Products at ASMBS 2Health News:VIDEO: Cancer Treatment Centers of America Selects Site in GA for Proposed Hospital Serving Patients in Southeast 2Health News:Traumatic brain injury caused by exposure to explosive blast presents critical challenge 2Health News:National All Schedules Prescription Electronic Reporting (NASPER) Act Receives Senate Support 2Health News:National All Schedules Prescription Electronic Reporting (NASPER) Act Receives Senate Support 3Health News:MedQuist Adds Kevin Piltz as New Chief Information Officer 2
    ... For many years, anyone using the Farnsworth D15, ... complained about how patients cannot avoid touching the ... kits become unusable. Further, the disks are very ... for these products in order to solve these ...
    ... Farnsworth Dichotomous testing sets are designed ... The Farnsworth D15 test is used to ... Normal. The L'Anthony Desaturated test is much ... mild deficiency from Normal. Both of ...
    ... is as easy as 1-2-3: just three simple ... satisfaction with rapid information before they leave your ... with the appropriate therapy; no more follow-up appointments ... Strep A Test is a rapid immunochromatographic assay ...
    12 mm single use, reloadable laparoscopic linear stapler with titanium staples....
    Medicine Products: